Physician profile
Alex Thomas
NPI 1265632574
$8,958.12
in general payments reported to CMS, 2019-2025
25 companies · $1,916 in 2025
The $1,916 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $999 · 2020: $766 · 2021: $910 · 2022: $1,208 · 2023: $1,610 · 2024: $1,550 · 2025: $1,916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,996 · Education: $79.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,996.14 |
| Education | $79.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,807.36 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $1,638.12 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,411.81 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $932.02 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $585.41 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $355.19 | 2019-2023 | Austedo |
| Csl Behring | $297.58 | 2019-2025 | Haegarda, Andembry |
| Nuvasive, INC. | $263.28 | 2019-2020 | |
| Biocryst US Sales Co., LLC | $234.14 | 2021-2025 | Orladeyo |
| Kaleo, INC. | $216.25 | 2020-2024 | Auvi-Q |
| Globus Medical, INC. | $212.01 | 2023-2025 | Excelsiusgps Robotic Navigation System |
| Genentech USA, INC. | $181.93 | 2019-2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $171.98 | 2025 | Neffy |
| Optinose US, INC. | $166.90 | 2019-2022 | |
| Amgen INC. | $86.97 | 2022-2024 | Tezspire |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $83.30 | 2023-2024 | Takhzyro, Cuvitru |
| Pfizer INC. | $81.41 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $57.48 | 2023 | |
| Alk-Abello, INC | $48.96 | 2019 | |
| Alexion Pharmaceuticals, INC. | $34.52 | 2025 | Strensiq |
| Phadia US INC. | $28.87 | 2019-2022 | |
| Pharming Healthcare, INC. | $21.24 | 2023 | Ruconest |
| Shire North American Group INC | $18.50 | 2019 | |
| Hospira, INC. | $11.59 | 2019 | |
| Circassia INC. | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.